Loading
Orthofix Medical Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by CAPPS VICKIE L, was filed 10 Mar 2026.
Orthofix Medical Inc.: what insiders have been doing
Orthofix Medical Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 43 filings came from 12 insiders.
On the market, 2 insiders bought (7 purchases totalling €1.5M) while 8 insiders sold (27 sales totalling €5.7M). Taken together, the sales exceed the purchases by €4.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The largest single trade was a sale of €2.2M by Juniper Investment Company, LLC, published on 29 May 2026, equal to 0.64% of the market capitalisation. The buyers include 1 major shareholder and 1 senior executive.
In all, 3 purchases were made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 10 March 2026, 227 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 43 filings in twelve months, the company is more active than the median of 24 filings across the 3,171 companies we follow on the same exchange. Since 2016, the database holds 29 purchases and 98 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 822.3 m USD of revenue and -92.2 m USD of net income.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
471
Thresholds
n/a
Buy Volume
€5M
29 ops. · all time
Sell Volume
€24M
98 ops. · all time
Who traded when
BuySaleGeoffrey C. Gillespie9 sales
Engine Capital Management, LP8 buys
Massimo Calafiore2 buys6 sales
Patrick Fisher6 sales
Juniper Investment Company, LLC5 sales
Jorge Andres Cedron4 sales
+6 other insiders
Since the insiders bought
- -19.6%Entry US$12.27 · Close at T+90 US$9.87
- -29.9%Entry US$13.53 · Close at T+90 US$9.49
- -11.7%Entry US$10.97 · Close at T+365 US$9.69
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Orthofix Medical Inc. Buy (bullish), based on 4 analysts. Average price target: US$13.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,502 of 26,248 companies
22.3
score / 100
Value16
Quality29
FCF yld-0.3%
Earn yld-23%
EV/EBITDA58.4x
ROE-14%
Gross mgn69%
Net mgn-11%
Debt/EBITDA18.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.85
Analyst consensus
4 analystsBuy
US$12.00Target US$13.00(+32%)US$14.00
Income statement
RevenueUS$822.3M
Gross profitUS$566M69% margin
EBITDAUS$9.9M1% margin
Net income-US$92.2M-7.4% margin
Valuation
PER (forward)26.6x
P/Book0.9x
Beta0.62
Balance sheet & cash
Market capUS$401.2M
Total debtUS$178.4M
Free Cash Flow-US$1.3M
Debt / Equity61%
Profitability & ownership
ROE-13.9%
ROA-2.7%
% insiders2.2%
% institutions95.9%
Last declaration on 5 October 2026
Declarations471 total
150 shares@ US$9.440.0004% mcap0.5% of flowCommon StockSEC:0001193125-26-414164:0
120,000 shares@ US$8.73930.26% mcap18.4% of flowCommon Stock, $0.10 par value per shareSEC:0001794034-26-000006:0
190,000 shares@ US$8.85990.42% mcap29.6% of flowCommon Stock, $0.10 par value per shareSEC:0001794034-26-000006:1
150 shares@ US$9.390.0004% mcap0.4% of flowCommon StockSEC:0001193125-26-381992:0
1,295 shares@ US$10.090.0033% mcap4.1% of flowCommon StockSEC:0001193125-26-359362:0
19,500 shares@ US$10.38380.052% mcap3.5% of flowCommon Stock, $0.10 par value per shareSEC:0001794034-26-000005:0
20,000 shares@ US$10.0130.051% mcap3.5% of flowCommon Stock, $0.10 par value per shareSEC:0001794034-26-000005:1
14,965 sharesCommon StockSEC:0001193125-26-269863:0
14,965 sharesCommon StockSEC:0001193125-26-269872:0
14,965 sharesCommon StockSEC:0001193125-26-269866:0
242,000 shares@ US$10.69920.64% mcap45.0% of flowCommon Stock, $0.10 par value per shareSEC:0001794034-26-000004:0
3,743 shares@ US$12.820.0098% mcap9.0% of flowCommon StockSEC:0001193125-26-163965:0
4,269 shares@ US$11.9236.1% of flowCommon StockSEC:0001193125-26-116071:0
100 shares@ US$12.442.0% of flowCommon StockSEC:0001193125-26-100156:1
Canonical exit: 8 Jun 2026 (T+90)
2,400 shares@ US$12.4547.7% of flowCommon StockSEC:0001193125-26-100156:2
Canonical exit: 8 Jun 2026 (T+90)
2,500 shares@ US$12.48100.0% of flowCommon StockSEC:0001193125-26-100156:0
Canonical exit: 7 Jun 2026 (T+90)
1,053 shares@ US$12.555.3% of flowCommon StockSEC:0001193125-26-096553:1
758 shares@ US$12.552.9% of flowCommon StockSEC:0001193125-26-096579:1
6,031 shares@ US$12.552.4% of flowCommon StockSEC:0001193125-26-096583:1
1,263 shares@ US$12.5521.9% of flowCommon StockSEC:0001193125-26-096568:1
2,363 shares@ US$12.554.2% of flowCommon StockSEC:0001193125-26-096594:1
1,370 shares@ US$12.553.2% of flowCommon StockSEC:0001193125-26-096547:1
1,141 shares@ US$12.559.1% of flowCommon StockSEC:0001193125-26-096590:1
1,171 shares@ US$12.916310.6% of flowCommon StockSEC:0001193125-26-096590:0
778 shares@ US$12.91633.2% of flowCommon StockSEC:0001193125-26-096579:0
25 of 471 declarations
About Orthofix Medical Inc.
Orthofix Medical Inc. is a U.S.-based medical technology company listed on the NASDAQ under the ticker OFIX, with corporate headquarters in Lewisville, Texas, United States. For European investors, Orthofix should be viewed as a specialized orthopedics and spine company focused on complex musculoskeletal conditions rather than a broad-based medtech conglomerate. The company traces its roots to 1980 in Verona, Italy, and has since evolved through several corporate milestones, including a later re-domestication to the United States in 2018 and a transformative merger of equals with SeaSpine completed in January 2023. That combination broadened the group’s scale and sharpened its identity as a global spine and orthopedics platform.
Orthofix’s portfolio is built around several complementary business lines: spinal implants, therapeutic solutions, limb reconstruction systems, biologics, and enabling technologies. Its product set includes spinal fixation systems, deformity correction solutions, bone growth therapies, limb reconstruction devices, and intraoperative navigation technologies such as the 7D FLASH Navigation System. Strategically, Orthofix occupies a niche position in the orthopedic medtech landscape. It is not the largest diversified player in the sector, but it competes on specialization, procedural relevance, surgeon relationships, and technology-led differentiation. The company’s competitive proposition is based on serving highly specific clinical needs where product performance, workflow efficiency, and surgical adoption matter materially.
Read moreShow less
Geographically, Orthofix has a broad international footprint, with products sold in more than 60 countries and a meaningful commercial and operational presence in the United States. Its global reach is supported by a combination of direct sales, distributor relationships, and partnerships with clinical organizations. Management has emphasized a focus on spine commercial channel optimization, deeper penetration of enabling technologies, and continued development of the limb reconstruction and biologics franchises. This mix gives the company exposure to both mature and growth-oriented orthopedic subsegments.
Recent developments have been important for the investment case. In February 2026, Orthofix reported full-year 2025 results and highlighted operational progress, improved adjusted EBITDA, and stronger free cash flow generation. In May 2026, the company reiterated guidance and said it was seeing steadier execution following spine commercial channel actions. Orthofix also announced the discontinuation of its M6 product lines, reallocating resources toward more profitable growth opportunities. At the same time, the company has been advancing launches and rollouts such as TrueLok Elevate and FITBONE, while continuing to focus on biologics and navigation technologies. Overall, Orthofix remains a specialized medtech name with a clear portfolio focus, international exposure, and a turnaround-and-growth narrative driven by product innovation, commercial execution, and margin improvement.
